U.S. stocks edge higher after weekly jobless claims; Salesforce gains
Dentsply Sirona Inc. (NASDAQ:XRAY) announced Tuesday the appointment of Michael Pomeroy as interim Chief Financial Officer. Pomeroy will serve in this temporary role while the company continues its search for a permanent CFO. The dental equipment manufacturer’s shares have struggled recently, falling over 41% year-to-date, though they’ve shown a modest 4.6% recovery in the past week.
According to a press release statement, Pomeroy will support Daniel T. Scavilla, Dentsply Sirona’s President and Chief Executive Officer, who will remain the company’s principal financial officer in addition to his responsibilities as principal executive officer until a permanent CFO is appointed.
Pomeroy brings experience from several industries, including industrial manufacturing, healthcare, consumer retail, and distribution. He began his career at GE, serving there from 1981 to 2000. Most recently, Pomeroy was interim CFO at Highridge Medical, a spinal devices company, from February 2025 to September 2025. His previous roles include Executive Vice President and CFO at Icahn Automotive Group (2022-2024), Executive Vice President and CFO at Hollander-Keeco (2021-2022), and Vice President and CFO at RGIS (2017-2021).
Dentsply Sirona, headquartered in Charlotte, North Carolina, is listed on the Nasdaq Stock Market under the ticker XRAY. The company, currently valued at $2.14 billion, has maintained dividend payments for 32 consecutive years and offers a significant 5.96% dividend yield. Despite posting a loss in the last twelve months, InvestingPro data shows analysts expect the company to return to profitability this year. With a current price of $10.73, the stock appears undervalued according to InvestingPro Fair Value metrics. Investors seeking deeper insights can access the comprehensive Pro Research Report, available for XRAY and 1,400+ other US equities.
In other recent news, Dentsply Sirona reported its third-quarter 2025 earnings, surpassing analysts’ expectations with an earnings per share (EPS) of $0.50, compared to the forecasted $0.45. Revenue also exceeded projections, coming in at $904 million against an anticipated $898.91 million. Despite these positive results, the company faced challenges, leading to a downgrade by William Blair from Outperform to Market Perform due to disappointing quarterly results and the unexpected departure of the CFO. The company cited lower volumes, an unfavorable product mix, and tariff impacts as reasons for missing earnings estimates by $0.08. Additionally, Dentsply Sirona lowered its full-year guidance, which contributed to Stifel reducing its price target from $15.00 to $13.00 while maintaining a Hold rating. The company’s 2025 guidance was also reduced, with the fourth-quarter outlook showing a notable decrease. CFO Matt Garth’s departure after about five months has further added to investor concerns, as the company now needs to search for a new chief financial officer. These developments have created an atmosphere of uncertainty among investors, despite the earnings beat.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.